

June 30, 2010
AnGes MG, Inc.

Published Paper Reporting the Results from Collatogene Phase III Clinical Trial Performed in Japan Receives the Research Achievement Award of the Asian Society for Vascular Surgery

AnGes MG, Inc. is pleased to announce that an academic paper, which was published in the medical journal “Gene Therapy (online version)” that reported the results of the data from the domestic phase III clinical trial of the HGF gene therapy product Collatogene for peripheral artery disease (arteriosclerosis obliterans [ASO]), received the Research Achievement Award of the 11th Annual Congress of Asian Society for Vascular Surgery.

This academic paper examined the efficacy and safety of Collatogene in patients with severe arteriosclerosis obliterans in a placebo-controlled, randomized, double-blind, comparative trial. The superiority of Collatogene to placebo was demonstrated in the primary endpoint, “Improvement rate in pain at rest or ischemic ulcer size after 12 weeks”. Concerning safety, there were no characteristic serious adverse reactions, including the post administration 15 months long-term follow-up period, and therefore the tolerability of Collatogene was shown. The results of this trial are available at <http://www.nature.com/gt/journal/vaop/ncurrent/abs/gt201051a.html>.

The Research Achievement Award was newly implemented by one of the society’s founders Dr. John B. Chang to commemorate the 11th Annual Congress of the Asian Society for Vascular Surgery. The academic paper featured in this release is the first to receive this prestigious award. Regarding the award, Dr. Hiroshi Shigematsu, Professor and Chairman of Tokyo Medical University who represented the authors gave the following comment: “Angiogenic therapy for critical limb ischemia is one of the most important topics in the treatment of vascular diseases in Asia. The fact that it has been so highly evaluated suggests the usefulness of HGF gene therapy.”

AnGes MG regards the award as a sign of the expectations for new therapies in areas where no improvements have been seen with existing therapies. The company would like to express its respect for the continuing efforts of people who have been involved in the implementation of the clinical trial, and also would like to make further efforts to be able to supply Collatogene at the earliest possible date.

Meanwhile, this trend will have no effect on AnGes MG’s business performance for the current fiscal year.